Skip to main content

Table 1 Comparison of clinical data in hospitalized NCFB patients with and without osteoporosis

From: Risk factors and prognostic value of osteoporosis in hospitalized patients with bronchiectasis

Clinical characteristics

With osteoporosis (n = 38)

Without osteoporosis (n = 141)

P value

Age (years)

74.00 (65.00, 78.25)

64.00 (52.50, 73.00)

 < 0.001

Sex (male %)

13 (34.21%)

82(58.16%)

0.009

BMI (kg/m2)

      < 18.5

14 (36.84%)

41 (29.08%)

0.336

      18.5–24

18 (47.37%)

62 (43.97%)

 

      ≥ 24 (%)

6 (23.08%)

38 (26.95%)

 

FEV1%pred

48.15 (39.70, 70.00)

60.30 (40.10, 87.45)

0.071

Current or ex-smokers (%)

13 (34.21%)

58 (41.13%)

0.439

Reiff score

8.00 (4.75, 12.00)

8.00 (4.00, 11.00)

0.959

Chronic infection by PA (%)

5 (13.16%)

17 (12.06%)

1.000

Chronic infection by pathogenic microorganisms (%)

7 (18.42%)

22 (15.60%)

0.676

mMRC (> 2 grade) (%)

14 (36.84%)

32 (22.70%)

0.077

Comorbidities

     COPD (%)

15 (39.47%)

41 (29.08%)

0.220

     Asthma (%)

5 (13.16%)

12 (8.51%)

0.579

     PAH (%)

10. 26 (32%)

34 (24.11%)

0.780

     HT (%)

10 (26.32%)

40 (28.37%)

0.802

     Diabetes (%)

5 (13.16%)

19 (13.48%)

0.959

     Sinusitis (%)

7 (18.42%)

23 (16.31%)

0.757

     GERD (%)

13 (34.21%)

20 (14.18%)

0.005

    CVD (%)

14 (36.84%)

27 (19.14%)

0.021

     Cerebrovascular disease (%)

4 (10.52%)

5 (3.55%)

0.184

     PVD (%)

3 (7.89%)

6 (4.26%)

0.622

     Kidney disease (%)

2 (5.26%)

9 (6.38%)

1.000

     Liver disease (%)

2 (5.26%)

20 (14.18%)

0.227

     Anemia (%)

16 (42.11%)

20 (14.18%)

 < 0.001

     CTD (%)

2 (5.26%)

13 (9.22%)

0.652

Post-infection(%)

14 (36.84%)

30 (21.28%)

0.048

Regular ICS treatment (%)

5 (38.46%)

17 (12.06%)

0.029

  1. Data are presented as frequency (%), mean ± standard deviation, or as median (interquartile range)
  2. NCFB non-cystic fibrosis bronchiectasis, BMI body mass index, FEV1%pre forced expiratory volume in 1 s to predictive value, PA Pseudomonas aeruginosa, mMRC modified Medical Research Council, COPD chronic obstructive pulmonary disease, PAH pulmonary artery hypertension, HT hypertension, GERD gastroesophageal reflux disease, CVD cardiovascular diseases, PVD Peripheral vascular disease, CTD, connective tissue disease, ICS inhaled corticosteroid